NYSE:MYOV

Stock Analysis Report

Executive Summary

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women’s health and endocrine diseases.

Rewards

Trading at 91.1% below its fair value

Risk Analysis

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months

Shareholders have been diluted in the past year



Snowflake Analysis

Slightly overvalued with weak fundamentals.

Share Price & News

How has Myovant Sciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MYOV's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-4.4%

MYOV

0.7%

US Biotechs

0.5%

US Market


1 Year Return

-47.2%

MYOV

15.7%

US Biotechs

20.3%

US Market

Return vs Industry: MYOV underperformed the US Biotechs industry which returned 15.7% over the past year.

Return vs Market: MYOV underperformed the US Market which returned 20.3% over the past year.


Shareholder returns

MYOVIndustryMarket
7 Day-4.4%0.7%0.5%
30 Day-19.6%2.7%2.0%
90 Day-20.1%8.7%9.4%
1 Year-47.2%-47.2%16.6%15.7%22.8%20.3%
3 Year3.9%3.9%25.3%21.9%50.1%40.4%
5 Yearn/a2.8%-1.9%73.1%54.1%

Price Volatility Vs. Market

How volatile is Myovant Sciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Myovant Sciences undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: MYOV ($11.26) is trading below our estimate of fair value ($125.81)

Significantly Below Fair Value: MYOV is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: MYOV is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: MYOV is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MYOV's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MYOV has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.


Next Steps

Future Growth

How is Myovant Sciences forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

53.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MYOV is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MYOV is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MYOV is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if MYOV's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if MYOV's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MYOV's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Myovant Sciences performed over the past 5 years?

-48.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MYOV is currently unprofitable.

Growing Profit Margin: MYOV is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MYOV is unprofitable, and losses have increased over the past 5 years at a rate of -48.9% per year.

Accelerating Growth: Unable to compare MYOV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MYOV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (64%).


Return on Equity

High ROE: MYOV's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Myovant Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: MYOV has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: MYOV has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: MYOV has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: MYOV's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: MYOV has a low level of unsold assets or inventory.

Debt Coverage by Assets: MYOV has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MYOV has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: MYOV has less than a year of cash runway if free cash flow continues to reduce at historical rates of -58.3% each year


Next Steps

Dividend

What is Myovant Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate MYOV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MYOV's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MYOV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MYOV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MYOV's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure


CEO

Lynn Seely (60yo)

3.8yrs

Tenure

US$4,434,302

Compensation

Dr. Lynn Seely, MD, serves as Principal Executive Officer at Myovant Sciences Ltd. and serves as its Executive Director and Chief Executive Officer. Dr. Seely had been the President of Myovant Sciences, In ...


CEO Compensation Analysis

Compensation vs Market: Lynn's total compensation ($USD4.43M) is above average for companies of similar size in the US market ($USD2.50M).

Compensation vs Earnings: Lynn's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Lynn Seely
Principal Executive Officer3.8yrsUS$4.43m1.88% $19.1m
Frank Karbe
President0.2yrsUS$2.24m0.0074% $74.8k
Matthew Lang
Chief Administrative and Legal Officer & Corporate Secretary0.2yrsUS$1.83m0.039% $389.5k
Juan Camilo Ferreira
Chief Medical Officer2.6yrsUS$1.98m0.0060% $60.5k
Kim Sablich
Chief Commercial Officer1.3yrsUS$2.36m0.066% $672.1k
Julie Tran
Senior Vice President of Human Resources0yrsno datano data
Bryan Selby
Senior Vice President of Product Development3.5yrsno datano data
Teresa Perney
Senior Vice President of Regulatory Affairs & Quality Assurance2.6yrsno datano data
Andria Langenberg
Head of Drug Safety & Pharmacovigilance2.6yrsno datano data
Jeffrey Nornhold
Senior VP of Pharmaceutical Operations & Development1.3yrsno datano data

2.6yrs

Average Tenure

51yo

Average Age

Experienced Management: MYOV's management team is considered experienced (2.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Lynn Seely
Principal Executive Officer3.8yrsUS$4.43m1.88% $19.1m
Myrtle Potter
Chairman of the Board1.3yrsUS$805.07kno data
Terrie Curran
Independent Director3.3yrsUS$405.54kno data
Adele Gulfo
Director0.2yrsno datano data
Kathleen Sebelius
Lead Independent Director1.6yrsUS$417.88k0.0056% $56.3k
Hiroshi Nomura
Director0.2yrsno datano data
Mark Guinan
Independent Director1.6yrsUS$625.29kno data

1.6yrs

Average Tenure

60yo

Average Age

Experienced Board: MYOV's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: MYOV insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26%.


Top Shareholders

Company Information

Myovant Sciences Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Myovant Sciences Ltd.
  • Ticker: MYOV
  • Exchange: NYSE
  • Founded: 2016
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.011b
  • Shares outstanding: 89.79m
  • Website: https://myovant.com

Number of Employees


Location

  • Myovant Sciences Ltd.
  • 11-12 St. James’s Square
  • Suite 1
  • London
  • Greater London
  • SW1Y 4LB
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MYOVNYSE (New York Stock Exchange)YesCommon SharesUSUSDOct 2016
71MDB (Deutsche Boerse AG)YesCommon SharesDEEUROct 2016

Biography

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women’s health and endocrine diseases. The company’s lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. As of December 27, 2019, Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.  


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/20 03:21
End of Day Share Price2020/02/19 00:00
Earnings2019/12/31
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.